Reviva Pharmaceuticals Holdings, INC

Reviva Pharmaceuticals announced Q1 2026 financial results, highlighting a provisional patent filing for a new form of brilaroxazine aimed at extending exclusivity until 2046 and upcoming FDA feedback.

Reviva Pharmaceuticals Holdings, Inc. will have its common stock delisted from The Nasdaq Capital Market effective May 14, 2026, and will begin trading on the OTCQB Venture Market.

Reviva Pharmaceuticals announced updates on its brilaroxazine program, including efforts to extend patent life and prepare for the next phase of development.

Reviva reported a narrower 2025 net loss, raised $10M in March 2026, and will run a second Phase 3 trial for brilaroxazine before an NDA filing for schizophrenia.

Reviva Pharmaceuticals Holdings, Inc. announced the pricing of a public offering raising $10 million in gross proceeds to fund R&D and general corporate purposes.

Reviva Pharmaceuticals Holdings, Inc. announced a one-for-twenty reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Reviva Pharmaceuticals reports Q1 2026 results, detailing a net loss of $3.2 million and significant cash burn, while preparing for Nasdaq delisting and transition to OTCQB.

Reviva Pharmaceuticals Holdings, Inc. reported a reduced net loss in Q3 2025 and advanced its lead drug candidate brilaroxazine, but faces Nasdaq delisting concerns and ongoing liquidity challenges.

Reviva Pharmaceuticals Holdings, Inc. reported a reduced net loss and successful clinical trial completions for brilaroxazine, but raised $9.7 million in new capital while facing substantial doubt about its ability to continue as a going concern and Nasdaq delisting threats.

Reviva Pharmaceuticals announces its Q1 2025 financial results, highlighting the progress of its lead drug candidate, brilaroxazine, and the need for additional funding to continue operations.

Reviva Pharmaceuticals' Q3 2024 report highlights a net loss, ongoing clinical trials for brilaroxazine, and recent capital raises to support operations.

Reviva Pharmaceuticals' Q2 2024 report details a net loss of $15.3 million, ongoing clinical trials, and a restatement of prior financial results.

Reviva Pharmaceuticals' 10-K filing highlights positive Phase 3 trial results for brilaroxazine in schizophrenia and outlines the company's strategy for potential FDA approval.

Reviva Pharmaceuticals' annual report outlines its share structure, warrant details, and a restatement of prior financial statements due to errors in recognizing research and development expenses.

Reviva Pharmaceuticals Holdings, Inc. CFO Narayan Prabhu was granted 40,925 stock options with an exercise price of $1.87, vesting over time.

Reviva Pharmaceuticals Holdings, Inc. CEO Laxminarayan Bhat received new stock option awards totaling 150,075 shares with an exercise price of $1.87.

Reviva Pharmaceuticals Holdings, Inc. director Leslie D. Funtleyder received a grant of 8,200 stock options with an exercise price of $0.5848.

Reviva Pharmaceuticals Holdings, Inc. director Richard A. Margolin was granted 8,200 stock options with an exercise price of $0.5848, vesting one year from the grant date.

Reviva Pharmaceuticals Holdings, Inc. director Purav Patel was granted 8,200 stock options with an exercise price of $0.5848, vesting one year from the grant date.

Reviva Pharmaceuticals Holdings, Inc. director Parag Saxena received 8,200 stock options with an exercise price of $0.5848, vesting in one year.

Reviva Pharmaceuticals Holdings, Inc. issued a supplement to its definitive proxy statement, correcting previously understated figures related to its proposed reverse stock split.

Reviva Pharmaceuticals Holdings, Inc. has filed a definitive proxy statement with the SEC.

Reviva Pharmaceuticals Holdings, Inc. calls its Annual Meeting to vote on a reverse stock split to maintain Nasdaq listing, an increase in authorized shares, and director elections.

Reviva Pharmaceuticals is holding its annual meeting on December 10, 2024, to vote on key proposals including increasing authorized shares and electing directors.

Parag Saxena has reduced his beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. to 2.8% as of March 20, 2026, triggering an Amendment No. 13 filing.

Vedanta Partners, LLC has reduced its beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. to below 5%, while Parag Saxena maintains a 5.2% stake.

Dr. Laxminarayan Bhat's beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. has decreased to 3.8%, falling below the 5% reporting threshold.

Vedanta Partners and Parag Saxena filed an Amendment No. 11 to their Schedule 13D, updating their beneficial ownership in Reviva Pharmaceuticals Holdings, Inc.

An amended Schedule 13D filing reveals that Vedanta Associates, L.P. has reduced its beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. to below the 5% threshold, while other affiliated entities and individuals maintain significant stakes.

Laxminarayan Bhat has filed Amendment No. 5 to his Schedule 13D, disclosing a beneficial ownership of 5.2% of Reviva Pharmaceuticals Holdings, Inc.'s common stock, totaling 3,612,384 shares.

Integrated Core Strategies, Millennium Management, and Israel A. Englander have jointly reported beneficial ownership of 8.2% of Reviva Pharmaceuticals Holdings, Inc. common stock.

UBS Group AG has filed a Schedule 13G, reporting no beneficial ownership of Reviva Pharmaceuticals Holdings, Inc. common stock as of June 30, 2026.

CVI Investments and Heights Capital Management report a combined 4.9% stake in Reviva Pharmaceuticals Holdings, Inc., primarily through warrants.

Barclays PLC has filed a Schedule 13G reporting a 5.96% beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc.

UBS Group AG has reported beneficial ownership of 746,095 shares, representing 5.8% of the outstanding common stock of Reviva Pharmaceuticals Holdings, Inc., as of March 31, 2026.

Millennium Management LLC and its affiliates have reported a 6.2% beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc.